Why Is PERSONALIS INC (PSNL) Stock Moving Today?

Why PSNL stock is moving today

Personalis Inc. (PSNL) shares are moving sharply lower today, down nearly 14% as of the latest trade at $13.40. The stock opened at $15.46 but quickly fell to a session low of $13.15 after the company announced a definitive agreement to be acquired by Tempus AI in a $1.5 billion deal. The transaction, disclosed in a Form 8-K filing and confirmed by multiple news outlets, involves a two-step merger that will integrate Personalis's cancer-monitoring capabilities with Tempus AI's oncology platform.

What Happened

Tempus AI announced the acquisition on July 20, 2026, with the goal of accelerating the development of molecular residual disease (MRD) monitoring solutions. The deal is expected to expand Tempus AI's precision oncology offerings, particularly through Personalis's NeXT test. The announcement triggered a trading halt for PSNL shares, which resumed with a significant sell-off. The CEO and other executives of Personalis have sold shares in recent weeks, with the most recent insider transaction reported on July 15. The stock’s decline reflects investor skepticism about the deal’s value despite the strategic rationale.

What The Data Shows

Personalis has a market cap of $1.6 billion but remains unprofitable with a trailing twelve-month EPS of -1.02 and a revenue decline of 24.7%. The stock has traded between $3.84 and $16.39 over the past 52 weeks. Today’s session has seen heavy volume of 6.1 million shares, more than double the 3-month average. The stock opened at $15.46 and quickly dropped to $13.15 before stabilizing slightly. The sell-off has been broad, with no unusual options activity reported and limited social media chatter.

What To Watch

Investors should monitor the execution of the merger and how the combined entity navigates the competitive landscape of cancer diagnostics. No earnings report is scheduled in the near term, but coverage breadth and market sentiment will be key to tracking the stock’s next move.